CHU La Timone
Département de Pharmacologie Clinique
Pr Olivier BLIN
Directeur du Centre de Pharmacologie Clinique et de Pharmacovigilance
Chargée de mission :
Neurodegenerative diseases affect over 33 million people worldwide. They are characterized by the progressive degeneration of neurons and dysfunction in the brain and / or spinal cord.
Their mechanisms (loss of neuronal cells, axonopathy, synaptic loss, inflammation, immune dysfunction ...) affect motor and cognitive functions (memory loss) and leave affected people to remain dependent on the help of others.
Since mainly people in their mid- to late life are affected, the impact of neurodegenerative diseases is likely to increase with the aging population. It is estimated that the number of people over 65 will represent one quarter of the European population by 2030.
In 2010, the medications treating these diseases accounted for 43% of the volume of medicines available on the market. However, most treatments are ineffective today, since mainly acting on the symptoms and not on the causes of these diseases and their evolution.
Due to the increased dependence of the patients, neurodegenerative diseases affect patients but also their families.
Natural process of life leading the body to be unable to perform its functions and its physiological balance.
A neurodegenerative disease resulting in progressive loss of neurons causing cognitive impairment and a progressive reduction in individual autonomy.
Neurodegenerative disease affecting the central nervous system, causing motor as well as non-motor impairments.
Autoimmune disease affecting the central nervous system. It causes lesions that cause motor, sensory and cognitive disturbances, which may progress to a growing handicap.
Disease caused by the progressive loss of motor neurons causing muscle weakness, difficulties in speaking and swallowing as well as problems breathing.
Neurodegenerative Disease resulting in impaired physical and intellectual abilities and also a loss of personal autonomy.